Pixantrone-d8 (maleate)
目录号 : GC52455An internal standard for the quantification of pixantrone
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Pixantrone-d8 is intended for use as an internal standard for the quantification of pixantrone by GC- or LC-MS. Pixantrone is a DNA topoisomerase II inhibitor.1 It induces SV40 DNA cleavage in the presence of mouse topoisomerase II and induces DNA single-strand breaks in NCI H187 cells in a concentration-dependent manner. Pixantrone is cytotoxic to L1210 leukemia cells as well as doxorubicin-sensitive and -resistant LoVo colon adenocarcinoma cells (IC50 = 0.01, 0.24, and 7.2 µg/ml, respectively).2 It decreases disease severity in a rat model of myasthenia gravis induced by immunization with the T. californica acetylcholine receptor (AChR) when administered at a dose of 8.12 mg/kg once per week for six weeks.3 Formulations containing pixantrone have been used in the treatment of non-Hodgkin B cell lymphoma.
1.De Isabella, P., Palumbo, M., Sissi, C., et al.Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivativesMol. Pharmacol.48(1)30-38(1995) 2.Krapcho, A.P., Petry, M.E., Getahun, Z., et al.6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: Synthesis and antitumor evaluationsJ. Med. Chem.37(6)828-837(1994) 3.Marolda, R., Ruocco, C., Cordiglieri, C., et al.Differential targeting of immune-cells by Pixantrone in experimental myasthenia gravisJ. Neuroimmunol.258(1-2)(2013)
| Cas No. | SDF | Download SDF | |
| Canonical SMILES | NC([2H])([2H])C([2H])([2H])NC1=C2C(C(C(C=CN=C3)=C3C2=O)=O)=C(NC([2H])([2H])C([2H])([2H])N)C=C1.OC(/C=C\C(O)=O)=O.OC(/C=C\C(O)=O)=O | ||
| 分子式 | C17H11D8N5O2 ? 2C4H4O4 | 分子量 | 565.6 |
| 溶解度 | DMSO: soluble,Methanol: soluble,Water: soluble | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.768 mL | 8.8402 mL | 17.6803 mL |
| 5 mM | 0.3536 mL | 1.768 mL | 3.5361 mL |
| 10 mM | 0.1768 mL | 0.884 mL | 1.768 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。